These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 1410925)

  • 1. [Pharmacological studies of sulbactam and its association with semisynthetic beta-lactam antibiotics].
    Nechifor M; Buiuc D; Diaconu E; Poiată A; Teslariu E; Filip C; Negru A; Antonescu C
    Rev Med Chir Soc Med Nat Iasi; 1992; 96(1-2):51-5. PubMed ID: 1410925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of beta-lactamase inhibitors on minimum inhibitory concentration of ampicillin and amoxicillin for Staphylococcus aureus strains.
    Paniagua GL; Monroy E; García O; Vaca S
    Rev Latinoam Microbiol; 1998; 40(3-4):128-34. PubMed ID: 10932741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison of the in vitro activity of amoxycillin + clavulanic acid and ampicillin + sulbactam combinations against 50 Haemophilus influenzae strains producing beta lactamase].
    Moittie D; Simonet M; Veron M
    Pathol Biol (Paris); 1989 May; 37(5):390-3. PubMed ID: 2789362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications of beta-lactamase-inhibitor combinations.
    Fuchs PC; Barry AL
    J Reprod Med; 1990 Mar; 35(3 Suppl):317-21. PubMed ID: 2319514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. beta-Lactam resistance phenotype determination in Escherichia coli isolates from University Malaya Medical Centre.
    Wong JS; Mohd Azri ZA; Subramaniam G; Ho SE; Palasubramaniam S; Navaratnam P
    Malays J Pathol; 2003 Dec; 25(2):113-9. PubMed ID: 16196367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulbactam: a beta-lactamase inhibitor.
    Noguchi JK; Gill MA
    Clin Pharm; 1988 Jan; 7(1):37-51. PubMed ID: 3278833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Stability of beta-lactamase inhibitors and beta-lactam antibiotics in parenteral formulations as well as in body fluids and tissue homogenates. Comparison of sulbactam, clavulanic acid, ampicillin and amoxicillin].
    Wildfeuer A; Räder K
    Arzneimittelforschung; 1991 Jan; 41(1):70-3. PubMed ID: 2049115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A comparison of the in vitro susceptibility of three bacteria to beta-lactamase inhibitors and to ampicillin and cefazolin].
    Acar N; Diri MC; Türkyilmaz FR
    Mikrobiyol Bul; 1987 Oct; 21(4):284-8. PubMed ID: 3332705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of beta-lactamase inhibitors.
    Sutherland R
    J Reprod Med; 1990 Mar; 35(3 Suppl):307-12. PubMed ID: 2319512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microbiological properties of sulbactam combined with ampicillin.
    Barba D; Galante D; Esposito S; Ruffilli MP
    Chemioterapia; 1987 Apr; 6(2):88-94. PubMed ID: 3036381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Errors of the agar diffusion method to predict Escherichia coli's susceptibility to ampicillin-sulbactam and amoxicillin-clavulanic acid].
    Villar HE; Jugo MB; Fernández-Lausi A; Farinati AE
    Enferm Infecc Microbiol Clin; 1996 May; 14(5):308-10. PubMed ID: 8744371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of beta-lactamase inhibitor sulbactam plus ampicillin against animal isolates of Pasteurella, Haemophilus, and Staphylococcus.
    Girard AE; Schelkly WU; Murphy KT; Sawyer PS
    Am J Vet Res; 1987 Dec; 48(12):1678-83. PubMed ID: 3501686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of in vitro susceptibility testing results for amoxicillin-clavulanate and ampicillin-sulbactam using a panel of beta-lactamase-producing Enterobacteriaceae.
    Siu LK; Cheng WL; Ho PL; Ng WS; Chau PY; Lo JY
    APMIS; 1998 Sep; 106(9):917-20. PubMed ID: 9808419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of drug resistance in Mycobacterium leprae by ampicillin/sulbactam.
    Prabhakaran K; Harris EB; Randhawa B; Hastings RC
    Microbios; 1992; 72(291):137-42. PubMed ID: 1287401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity against clinically important gram-positive and gram-negative bacteria of sulbactam, alone and in combination with ampicillin, cefotaxime, mezlocillin, and piperacillin.
    Schmalreck AF; Wildfeuer A
    Arzneimittelforschung; 1990 Oct; 40(10):1145-55. PubMed ID: 2291754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacokinetic and clinical research on a new antibiotic combination (amoxicillin and flucloxacillin in equivalent-weight dose)].
    Di Nola F; Soranzo ML; Bosio G; Sachelariu N; Mastroviti S
    Minerva Med; 1977 Mar; 68(14):917-28. PubMed ID: 321992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational antibiotic therapy and the position of ampicillin/sulbactam.
    Lode HM
    Int J Antimicrob Agents; 2008 Jul; 32(1):10-28. PubMed ID: 18539004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation by scanning electron microscopy of in vitro and in vivo effects of amoxicillin and ampicillin on the morphology of Escherichia coli.
    Kramer MJ; Mauriz VR
    Scan Electron Microsc; 1979; (3):33-40. PubMed ID: 392705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming resistance to beta-lactamase inhibitors: comparing sulbactam to novel inhibitors against clavulanate resistant SHV enzymes with substitutions at Ambler position 244.
    Thomson JM; Distler AM; Bonomo RA
    Biochemistry; 2007 Oct; 46(40):11361-8. PubMed ID: 17848099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.